The estimated Net Worth of Richard J Benjamin is at least 2.55 百万$ dollars as of 2 August 2024. Richard Benjamin owns over 21,605 units of Cerus stock worth over 897,914$ and over the last 9 years he sold CERS stock worth over 386,778$. In addition, he makes 1,261,460$ as Chief Medical Officer at Cerus.
Richard has made over 15 trades of the Cerus stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 21,605 units of CERS stock worth 54,013$ on 2 August 2024.
The largest trade he's ever made was exercising 165,000 units of Cerus stock on 3 November 2021 worth over 752,400$. On average, Richard trades about 31,127 units every 78 days since 2015. As of 2 August 2024 he still owns at least 438,007 units of Cerus stock.
You can see the complete history of Richard Benjamin stock trades at the bottom of the page.
Dr. Richard J. Benjamin Ph.D. serves as Chief Medical Officer of the Company. From January 2006 to June 2015, he served as Chief Medical Officer for the American Red Cross, where he oversaw donor and patient safety issues for approximately 40% of the US blood supply. Dr. Benjamin is a Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the American Association of Blood Banks. He has also served on the DHHS Secretary’s Advisory Committee on Blood Safety and Availability in the U.S. from since December 2016 and previously served on the committee from 2006 to 2007. Dr. Benjamin is an Adjunct Full Professor of Pathology at Georgetown University and author of over 100 peer-reviewed publications. He received his Ph.D. at Cambridge University, England in Immunology and completed post-doctoral research at Stanford University.
As the Chief Medical Officer of Cerus, the total compensation of Richard Benjamin at Cerus is 1,261,460$. There are 3 executives at Cerus getting paid more, with William Greenman having the highest compensation of 3,270,180$.
Richard Benjamin is 60, he's been the Chief Medical Officer of Cerus since 2015. There are 6 older and 6 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Richard's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: